Nevada
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Data by race/ethnicity are not available for Nevada.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Nevada is not available over this period.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Nevada is 26.6%, which is significantly lower than the national rate of 28.4%.
- It ranks 29th among the 47 states with survival data, placing it in the below average tier.
- Over the last five years, the survival rate in Nevada improved by 34%.
Early Diagnosis:
- 21.5% of cases are caught at an early stage, which is significantly lower than the national rate of 27.4%.
- It ranks 42nd among the 47 states with data on diagnosis at an early stage, placing it in the bottom tier.
- Over the last five years, the early diagnosis rate in Nevada did not change significantly.
Lung Cancer Treatment
Surgical Treatment:
- Nevada ranked 46th (out of the 47 states with available data) with 14.3% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 20.7% and puts Arizona in the bottom tier.
- Over the last five years, the percent of cases undergoing surgery in Nevada did not change significantly.
Biomarker Coverage:
- Nevada has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2024.
Lack of Treatment:
- Nevada ranked 47th (out of the 47 states with available data) with 36.7% of cases not receiving any treatment.
- This is significantly higher than the national rate of 20.9% and puts Nevada in the bottom tier.
- Over the last five years, the percent of cases receiving no treatment in Nevada increased by 35%.
Screening
Screening for High Risk:
- In Nevada, 12.3% of those at high risk were screened, which was not significantly different than the national rate of 16.0%.
- It ranks 43rd among all states, placing it in the below average tier.
Prevention
Tobacco Use:
- The smoking rate in Nevada is 14.8% and not significantly different than the national rate of 12.9%.
- It ranks 31stamong all states, placing it in the below average tier.
Radon:
- In Nevada, 12.8% of radon tests results were at or above the action level recommended by EPA.
- It ranks 12th among all states, placing it in the above average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 46.7 per 100,000 population among Black individuals in Nevada, significantly lower than the rate of 55.1 among Black individuals nationally, and not significantly different than the rate of 50.6 among white individuals in Nevada.
- The five-year survival rate is 22.0% among Black individuals in Nevada, not significantly different than the rate of 25.5% among Black individuals nationally, and not significantly different than the rate of 26.4% among white individuals in Nevada.
- 18.3% of lung cancer cases are diagnosed at an early stage among Black individuals in Nevada, significantly lower than the rate of 24.1% among Black individuals nationally, and significantly lower than the rate of 22.4% among white individuals in Nevada.
- 13.3% of Black individuals with lung cancer in Nevada underwent surgery, significantly lower than the rate of 17.0% among Black individuals nationally, and not significantly different than the rate of 14.3% among white individuals in Nevada.
- 39.6% of Black individuals with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 36.1% among white individuals in Nevada.
Latino individuals:
- The rate of new lung cancer cases is 25.5 per 100,000 population among Latino individuals in Nevada, not significantly different than the rate of 28.1 among Latino individuals nationally, and significantly lower than the rate of 50.6 among white individuals in Nevada.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 17.7% of lung cancer cases are diagnosed at an early stage among Latino individuals in Nevada, significantly lower than the rate of 23.5% among Latino individuals nationally, and significantly lower than the rate of 22.4% among white individuals in Nevada.
- 12.0% of Latino individuals with lung cancer in Nevada underwent surgery, significantly lower than the rate of 21.3% among Latino individuals nationally, and significantly lower than the rate of 14.3% among white individuals in Nevada.
- 38.6% of Latino individuals with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 26.3% among Latino individuals nationally, and not significantly different than the rate of 36.1% among white individuals in Nevada.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 30.8 per 100,000 population among Asian or Pacific Islanders individuals in Nevada, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 50.6 among white individuals in Nevada.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 19.0% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Nevada, significantly lower than the rate of 23.4% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 22.4% among white individuals in Nevada.
- 17.0% of Asian or Pacific Islander individuals with lung cancer in Nevada underwent surgery, significantly lower than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 14.3% among white individuals in Nevada.
- 38.0% of Asian or Pacific Islander individuals with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 20.1% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 36.1% among white individuals in Nevada.
Indigenous Peoples:
- The rate of new lung cancer cases is 22.7 per 100,000 population among Indigenous Peoples (American Indians/Alaska Natives) in Nevada, significantly lower than the rate of 39.9 among Indigenous Peoples nationally, and significantly lower than the rate of 50.6 among white individuals in Nevada.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- 35.7% of Indigenous Peoples (American Indians/Alaska Natives) with lung cancer in Nevada did not receive any treatment, not significantly different than the rate of 24.3% among Indigenous Peoples (American Indians/Alaska Natives) nationally, and not significantly different than the rate of 36.1% among white individuals in Nevada.
- Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Nevada due to too few cases over the time period to allow for accurate analysis.
Summary
The early diagnosis rate in Nevada falls into the bottom tier. The state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Nevada has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
It is alarming that Nevada falls into the bottom tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 12, 2024